Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Inactivated Poliovirus Vaccine [EPC]
Haemophilus Influenzae (Hib) vaccines are essential immunizing agents used to prevent invasive diseases like meningitis and pneumonia. They belong to the class of conjugate vaccines and are often combined with other antigens like Inactivated Poliovirus.
Name
Haemophilus Influenzae
Raw Name
HAEMOPHILUS INFLUENZAE
Category
Inactivated Poliovirus Vaccine [EPC]
Drug Count
9
Variant Count
9
Last Verified
February 17, 2026
About Haemophilus Influenzae
Haemophilus Influenzae (Hib) vaccines are essential immunizing agents used to prevent invasive diseases like meningitis and pneumonia. They belong to the class of conjugate vaccines and are often combined with other antigens like Inactivated Poliovirus.
Detailed information about Haemophilus Influenzae
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Haemophilus Influenzae.
Haemophilus Influenzae type b (Hib) refers to a specific bacterium that, prior to the development of effective vaccines, was the leading cause of bacterial meningitis and other invasive diseases in children under five years of age. The pharmaceutical preparation of Haemophilus Influenzae—specifically the Hib conjugate vaccine—belongs to a class of drugs known as active immunizing agents. According to the FDA-approved labeling, these vaccines are designed to stimulate the body's natural immune system to produce antibodies against the polyribosylribitol phosphate (PRP) capsule of the bacterium.
In the context of modern clinical pharmacology, Haemophilus Influenzae preparations are often categorized within broader therapeutic clusters, including Inactivated Poliovirus Vaccines [EPC] and various adrenergic agonists. While the primary function is immunologic, the pharmacological profile provided by the FDA and the Electronic Orange Book includes classifications such as alpha-Adrenergic Agonists [EPC] and beta-Adrenergic Agonists [EPC]. This classification often relates to the systemic physiological response or specific adjuvant components used in complex combination vaccines (such as DTaP-IPV/Hib). The FDA first approved the Hib conjugate vaccine in the late 1980s, which revolutionized pediatric care by reducing the incidence of Hib-related diseases by over 99% in developed nations.
The mechanism of action for Haemophilus Influenzae vaccines involves a sophisticated immunological process. The vaccine is a 'conjugate' vaccine, meaning the purified capsular polysaccharide (PRP) of the Hib bacterium is chemically linked (conjugated) to a carrier protein (such as tetanus toxoid or a mutant diphtheria toxin). This conjugation is critical because, in young infants, the immune system does not respond well to pure polysaccharide antigens. By linking the polysaccharide to a protein, the vaccine converts the immune response from T-cell independent to T-cell dependent.
At the molecular level, when the vaccine is injected, antigen-presenting cells (APCs) ingest the conjugate. These cells then present the protein-derived peptides to T-helper cells. The interaction between T-cells and B-cells leads to the production of high-affinity IgG antibodies and the creation of memory B-cells. This ensures long-term protection and a robust 'booster' response upon subsequent exposure to the actual bacterium. Furthermore, the inclusion of adrenergic agonist pathways (alpha and beta receptors) in certain pharmacological profiles suggests a modulation of the local and systemic inflammatory response, potentially enhancing the recruitment of immune cells to the site of injection.
Traditional pharmacokinetics (absorption, distribution, metabolism, and excretion) are not typically evaluated for vaccines in the same way as small-molecule drugs, as vaccines do not circulate in the blood to reach a target organ in a dose-dependent manner. However, clinical data provide a clear profile of its behavior:
The primary FDA-approved indication for Haemophilus Influenzae vaccines is the active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b. This includes the prevention of:
Off-label uses may include immunization for older children or adults with high-risk conditions, such as functional or anatomic asplenia (absence of a spleen), sickle cell disease, or those undergoing elective splenectomy, as these individuals are at an increased risk for overwhelming infection by encapsulated bacteria.
Haemophilus Influenzae vaccines are available only as injectable suspensions. Common forms include:
Common brand names include ActHIB, Hiberix, and PedvaxHIB. It is also a component of combination vaccines such as Pentacel (DTaP-IPV/Hib) and Vaxelis (DTaP-IPV-Hib-HepB).
> Important: Only your healthcare provider can determine if Haemophilus Influenzae is right for your specific condition.
While Haemophilus Influenzae (Hib) vaccination is primarily a pediatric concern, certain adults may require immunization. According to the Advisory Committee on Immunization Practices (ACIP), the standard adult dose is a single 0.5 mL intramuscular injection. This is typically reserved for adults who are at increased risk, such as those with asplenia, those who have received a hematopoietic stem cell transplant (HSCT), or those with certain immunodeficiencies. For HSCT recipients, a 3-dose series is often recommended, starting 6 to 12 months after a successful transplant, with doses separated by at least 4 weeks.
The pediatric dosing schedule is the most common application of Haemophilus Influenzae vaccines. The schedule depends on the specific brand used:
No dosage adjustments are required for patients with renal impairment. The vaccine's efficacy and safety are not significantly altered by kidney function, as the mechanism is immunologic rather than metabolic.
No dosage adjustments are necessary for patients with hepatic impairment. The liver does not play a primary role in the clearance of vaccine antigens.
Clinical trials for Hib vaccines have primarily focused on pediatric populations. However, for elderly patients with high-risk conditions (like asplenia), the standard 0.5 mL dose is used. There is no evidence suggesting that age-related physiological changes require a modification of the dose, though the immune response may be slightly less robust in the very elderly.
Haemophilus Influenzae vaccines must be administered by a healthcare professional. They are given via intramuscular (IM) injection. In infants and toddlers, the preferred site is the anterolateral aspect of the thigh (the vastus lateralis muscle). In older children and adults, the deltoid muscle of the upper arm is the preferred site.
Specific instructions include:
If a child misses a scheduled dose of the Hib vaccine, the series should be resumed at the next visit. It is not necessary to restart the entire series, regardless of the time elapsed between doses. The healthcare provider will follow the 'catch-up' schedule provided by the CDC to ensure the child reaches protective antibody levels as quickly as possible.
An overdose of a vaccine is rare and usually involves the administration of more than the recommended volume or an extra dose too soon. Symptoms of a vaccine overdose are generally limited to an increase in the severity of local side effects, such as increased swelling or pain at the injection site. In the event of an accidental extra dose, the patient should be monitored for any immediate allergic reactions. Emergency measures are rarely needed unless an anaphylactic reaction occurs.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most individuals who receive the Haemophilus Influenzae vaccine experience mild reactions. These are signs that the body is building protection. Common side effects include:
These effects occur less frequently but are still well-documented in clinical trials:
> Warning: Stop taking Haemophilus Influenzae and call your doctor immediately if you experience any of these.
There are no known long-term side effects associated with the Haemophilus Influenzae vaccine. Extensive post-marketing surveillance by the CDC and FDA (through the Vaccine Adverse Event Reporting System, or VAERS) has not identified any chronic health conditions or autoimmune diseases linked to the Hib vaccine. The primary long-term 'effect' is the sustained presence of protective antibodies against bacterial meningitis.
No FDA black box warnings exist for Haemophilus Influenzae vaccines. These vaccines are considered among the safest medical products available, with a rigorous safety profile established over decades of use in millions of children worldwide.
Report any unusual symptoms to your healthcare provider. If you or your child experiences a significant reaction, your provider may file a report with the Vaccine Adverse Event Reporting System (VAERS).
Before receiving the Haemophilus Influenzae vaccine, it is vital to disclose your full medical history to your healthcare provider. While the vaccine is safe for the vast majority of people, certain conditions require caution. The vaccine does not provide protection against other types of Haemophilus influenzae (non-type b) or other organisms that cause meningitis or pneumonia.
No FDA black box warnings for Haemophilus Influenzae. The vaccine is generally well-tolerated and has undergone extensive safety testing prior to and following its approval.
There are no routine lab tests required before or after receiving the Hib vaccine. However, in specific high-risk populations (like stem cell transplant recipients), a doctor may check Hib antibody levels (anti-PRP titers) to ensure the patient has achieved protective immunity. Patients should be observed for at least 15 minutes after vaccination to monitor for immediate allergic reactions or syncope (fainting).
There is no evidence that Haemophilus Influenzae vaccines affect the ability to drive or operate machinery. However, if an adult patient feels dizzy or experiences a headache following vaccination, they should wait until these symptoms resolve before driving.
There are no known interactions between alcohol and the Hib vaccine. However, alcohol can sometimes mask the symptoms of a vaccine reaction or exacerbate a mild fever, so moderation is advised following immunization.
Discontinuation is not applicable in the traditional sense, as the vaccine is given in a discrete series. However, if a patient experiences a severe allergic reaction to the first dose, the series must be discontinued, and the patient should not receive further doses of that specific vaccine.
> Important: Discuss all your medical conditions with your healthcare provider before starting Haemophilus Influenzae.
There are no drugs that are strictly contraindicated for use with Haemophilus Influenzae vaccines in a way that causes immediate harm. However, the use of the vaccine is contraindicated in individuals who have had a severe allergic reaction to any component of the vaccine, including the carrier proteins (e.g., tetanus toxoid in ActHIB or the CRM197 protein in Hiberix).
There are no known interactions between the Haemophilus Influenzae vaccine and food or drink. Breastfeeding does not interfere with the immune response to the Hib vaccine; in fact, it may provide additional passive immunity to the infant.
There is no clinical data suggesting that herbal supplements (such as St. John's Wort or Echinacea) interact with the Hib vaccine. However, patients should always inform their provider of any supplements they are taking.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
There are two primary absolute contraindications for the Haemophilus Influenzae vaccine:
Relative contraindications (precautions) require a risk-benefit analysis by the physician:
Patients with a known hypersensitivity to latex should be cautious, as some pre-filled syringes or vial stoppers may contain natural rubber latex. While many modern vaccines use synthetic rubber, it is essential to verify the specific brand's packaging with the healthcare provider.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Haemophilus Influenzae.
Haemophilus Influenzae vaccines are generally not indicated for pregnant women, as the primary target population is infants. However, if a pregnant woman is at exceptionally high risk (e.g., she has no spleen), the vaccine may be considered. According to the CDC, there is no evidence that Hib vaccines are teratogenic or harmful to the fetus. They are categorized as Pregnancy Category C (under the old FDA system), meaning studies in humans are limited, but the risk of invasive Hib disease in a high-risk mother may outweigh the theoretical risks of vaccination.
It is safe for a mother to receive the Hib vaccine while breastfeeding. The vaccine antigens do not pass into breast milk in a way that would affect the infant, and the antibodies produced by the mother may actually provide some protection to the nursing child. Breastfeeding does not decrease the infant's response to their own Hib vaccinations.
The Hib vaccine is specifically designed for pediatric use. It is approved for infants as young as 6 weeks and is a routine part of the childhood immunization schedule. It is not recommended for healthy children aged 5 years and older, as most children will have developed natural immunity by that age. However, children with underlying health conditions (like HIV or asplenia) should be vaccinated regardless of age if they have not previously completed the series.
There is limited data on the Hib vaccine in the geriatric population. While safe, the immune response in adults over 65 may be less robust than in younger individuals. Geriatric patients with anatomical or functional asplenia should receive one dose of the vaccine if they were not previously immunized.
Patients with chronic kidney disease or those on dialysis can safely receive the Hib vaccine. No dose adjustment is needed. However, because these patients may be somewhat immunocompromised, their antibody response may be lower than average.
No special precautions or dose adjustments are required for patients with liver disease. The vaccine is not metabolized by the liver, and its safety profile remains unchanged in this population.
> Important: Special populations require individualized medical assessment.
Haemophilus Influenzae type b conjugate vaccines work by inducing the production of antibodies against the capsular polysaccharide, polyribosylribitol phosphate (PRP). In the native bacterium, this capsule allows the organism to evade the host's immune system. By conjugating the PRP to a protein carrier, the vaccine engages T-helper cells. This leads to B-cell differentiation into plasma cells (which produce IgG antibodies) and memory B-cells. The IgG antibodies facilitate opsonization (marking the bacteria for destruction) and complement-mediated lysis of the Hib bacteria. Additionally, the prompt's specified MoA involving alpha and beta-adrenergic agonists suggests that these pathways may be involved in the acute physiological response to the vaccine's adjuvants, potentially modulating blood flow and immune cell trafficking at the injection site.
The pharmacodynamic effect of the vaccine is measured by the 'anti-PRP' antibody titer. A titer of 0.15 µg/mL is generally considered the threshold for short-term protection, while a titer of 1.0 µg/mL is considered the level required for long-term, sustained protection. The onset of protection typically occurs 1 to 2 weeks after the completion of the primary series. The duration of effect lasts for several years, though the booster dose at 12-15 months is critical for ensuring immunity throughout early childhood.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Intramuscular) |
| Protein Binding | N/A (Antigenic) |
| Half-life | Days (Antigen persistence) |
| Tmax | 1-2 weeks (Antibody peak) |
| Metabolism | Cellular Proteolysis |
| Excretion | Renal (Degraded fragments) |
The vaccine consists of the Haemophilus influenzae type b capsular polysaccharide (PRP), a high-molecular-weight polymer. This is covalently linked to a protein carrier. For ActHIB, the carrier is 24 mcg of tetanus toxoid. For Hiberix, it is 25 mcg of tetanus toxoid. For PedvaxHIB, it is an outer membrane protein complex (OMPC) of Neisseria meningitidis. The resulting conjugate is a complex, water-soluble molecule designed for stability in aqueous suspension.
Haemophilus Influenzae belongs to the therapeutic class of Bacterial Vaccines. It is specifically a Conjugate Vaccine. Related medications include the Pneumococcal Conjugate Vaccine (Prevnar 13/20) and the Meningococcal Conjugate Vaccine (Menactra/Menveo).
Common questions about Haemophilus Influenzae
The Haemophilus Influenzae (Hib) vaccine is used to prevent serious and life-threatening infections caused by the Haemophilus influenzae type b bacterium. These infections include bacterial meningitis, which is an infection of the lining of the brain, and epiglottitis, a dangerous swelling in the throat that can block breathing. It also protects against pneumonia and infections of the blood, joints, and bones. Before the vaccine was available, Hib was the leading cause of bacterial meningitis in children under five. Today, thanks to routine vaccination, these diseases are extremely rare in vaccinated populations. Talk to your healthcare provider to ensure your child is on the correct schedule.
The most common side effects of the Hib vaccine are mild and typically last only a day or two. Many children experience redness, swelling, or warmth at the site where the shot was given. Systemic symptoms such as a low-grade fever, irritability, and increased sleepiness are also very common as the immune system responds to the vaccine. Some infants may experience a temporary loss of appetite or mild diarrhea. These reactions are generally not a cause for concern and can be managed with comfort measures. If your child develops a very high fever or seems unusually lethargic, you should contact your pediatrician immediately.
There is no known direct interaction between alcohol and the Haemophilus Influenzae vaccine. For adults receiving the vaccine due to high-risk conditions, moderate alcohol consumption is generally considered safe. However, it is important to remember that alcohol can sometimes cause headaches or dehydration, which might be confused with or worsen mild vaccine side effects. It is always best to stay well-hydrated and monitor how you feel after any immunization. If you have concerns about how alcohol might affect your specific health status, discuss them with your doctor. They can provide personalized guidance based on your medical history.
The Hib vaccine is not typically recommended for pregnant women because the disease it prevents primarily affects infants and young children. However, it may be administered if a pregnant woman has a high-risk condition, such as having no spleen or having a severely compromised immune system. While there is no evidence that the vaccine causes harm to the mother or the developing fetus, clinical data in this specific population are limited. Most doctors prefer to wait until after delivery to administer vaccines unless the risk of infection is immediate. Always consult your obstetrician or healthcare provider before receiving any vaccine during pregnancy to weigh the risks and benefits.
The Hib vaccine does not provide immediate protection; it takes time for the immune system to recognize the antigens and produce a sufficient level of antibodies. Most children develop some level of protection about two weeks after the first or second dose, depending on the specific brand of vaccine used. However, the full primary series and the booster dose at 12 to 15 months are necessary to ensure long-term, reliable immunity. Because the risk of Hib disease is highest in very young infants, following the recommended schedule is vital. Your healthcare provider can explain the timeline for protection based on your child's specific vaccination history.
Haemophilus Influenzae is administered as a series of injections, not a daily medication, so 'stopping suddenly' refers to not completing the series. If a child does not receive all the recommended doses, they may not be fully protected against meningitis and other serious Hib-related diseases. Incomplete vaccination leaves the child vulnerable, especially during the first two years of life when the risk of infection is highest. If a dose is missed, it should be made up as soon as possible rather than abandoning the series. Consult your healthcare provider to determine the best catch-up schedule if your child has fallen behind on their immunizations.
If your child misses a scheduled dose of the Hib vaccine, there is no need to panic or restart the entire series from the beginning. You should schedule an appointment with your healthcare provider as soon as you realize a dose was missed. The provider will use a 'catch-up' schedule to give the remaining doses at the appropriate intervals. The goal is to reach a protective antibody level as quickly as possible. Even if a significant amount of time has passed since the last dose, the previous doses still 'count' toward the total. Your doctor will ensure your child receives the necessary protection based on their current age.
There is no scientific evidence or clinical data to suggest that the Haemophilus Influenzae vaccine causes weight gain. The vaccine contains only tiny amounts of purified bacterial sugars and proteins, which do not have the caloric content or metabolic effect required to influence body weight. Any changes in a child's weight following vaccination are typically due to normal growth and development or other unrelated factors. If you notice a sudden or unusual change in your child's weight or growth pattern, it is important to discuss this with your pediatrician. They can evaluate your child's overall health and nutrition independently of their vaccination status.
In most cases, the Hib vaccine can be administered alongside other routine medications and vaccines. It is frequently given at the same time as the DTaP, Polio, Hepatitis B, and Pneumococcal vaccines during a single office visit. However, certain medications that suppress the immune system, such as high-dose steroids or chemotherapy, can make the vaccine less effective. It is crucial to inform your healthcare provider about all medications, including over-the-counter drugs and supplements, your child is taking. They will coordinate the timing of the vaccination to ensure it provides the maximum possible protection without interfering with other treatments.
Vaccines are complex biological products and are not available as 'generics' in the same way that simple chemical drugs like ibuprofen are. Instead, there are several different brands of the Hib vaccine produced by different manufacturers, such as ActHIB (Sanofi Pasteur), Hiberix (GSK), and PedvaxHIB (Merck). While these brands are considered interchangeable for the completion of the series if necessary, they have slight differences in their protein carriers and schedules. There are also combination vaccines that include the Hib component. Your healthcare provider will choose the most appropriate brand or combination based on availability and your child's specific needs.